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ABSTRACT
Xenematide, a cyclic depsipeptide antibiotic produced by Xenorhabdus nematophila, had a candidate nonribosomal peptide synthetase (NRPS)
with atypical features. Differential metabolite analysis between a mutant and wildtype validated that this stand-alone NRPS was required for
xenematide production, and further analysis led to a series of new xenematide derivatives encoded by the same NRPS. Our results indicate that
adenylation domain promiscuity and relaxed downstream processing in the X. nematophila NRPS provide a conduit for xenematide
diversification.
BacteriabelongingtotheXenorhabdusgenusengageina
mutualistic symbiosis with insect-pathogenic Steinernema
nematodes.
1 After invading an insect host, the nematode
regurgitates the bacteria into the host’s amino acid rich
circulatory system (hemolymph). The released bacteria
produce a m  elange of small molecules that regulate the
insect bacteria nematode symbiosis in which the bacter-
ia and nematode prosper by cooperatively killing and
consuming the dead insect. The bacteria also synthesize
small molecule antimicrobials to reduce competition. We
recentlydiscoveredthat L-proline,anabundantaminoacid
in insect hemolymph, contributes to the bacterial proton
motive force and upregulates the production of secondary
metabolitesinPhotorhabdusluminescensTT01andXenor-
habdus nematophila 19061.
2 Xenematide A (9), a cyclic
depsipeptide with antibacterial activity against both
Gram-negative and Gram-positive bacteria,
3 is one of the
dramatically upregulated metabolites in X. nematophila.
2
Here we identify the nonribosomal peptide synthetase
(NRPS) responsible for xenematide biosynthesis, discover
a small family of new xenematide derivatives originating
from substrate promiscuity in the NRPS pathway, and
propose a unified biosynthesis for xenematide assembly.
Xenematide A (9), which incorporates the nonproteino-
genic amino acid β-Ala and a phenylacetate (PAA) starter
unit, would most plausibly arise from an NRPS pathway
rather than a ribosomal pathway. NRPS pathways are
modular enzymatic assembly lines whose products can
largely be predicted from the number and order of their
modules and the specific domains within each module
according to the colinearity rule.
4 In an ATP-consuming
reaction, adenylation (A) domains link free amino acid
building blocks onto their cognate peptidyl carrier protein
(PCP; or T, thiolation) domains through the formation of
a thioester bond to a phosphopantetheinyl prosthetic
group.TheaminoacidspecificityencodedbyanAdomain
can frequently be predicted from gene sequence alone.
5
Condensation (C) domains catalyze amide bond forma-
tion, and the nonproteinogenic peptide is elongated
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sequentially in the order dictated by the domain sequence
in the NRPS protein(s). Some NRPS systems contain
epimerization (E) or specialized condensation/epimeriza-
tion (C/E) domains to introduce D-amino acids into the
final product. Based on xenematide’s 2-phenylacetamide-
substituted cyclic tetrapeptide sequence, we initially ex-
pected a clustered five module NRPS system for the
loading of a PAA starter unit and for the stepwise con-
densation of Thr, Trp, Trp, and β-Ala. Bioinformatic
analysis of all of the NRPS genes in the X. nematophila
19061 genome led to a stand-alone four module NRPS
(XNC1_2713, Accession YP_003712913) as the most
likely candidate. Comparisons to the conserved domain
database (CDD) indicated that the 4949 amino acid
protein contained a C-A-T initiation module, two canoni-
cal C-A-T extender modules, and an atypical C-C/E-A-T-
TE termination module. The termination module har-
bored tandem C-C/E domains witha small internalspacer
sequence. Using the online tool NRPSpredictor,
5c the
adenylation domain sequences were closest to domains
that accept Thr-Trp-Trp-β-Ala, as expected. An initiation
module for the PAA starter unit was lacking.
To determine if NRPS XNC1_2713 was indeed respon-
sibleforxenematidebiosynthesis,weknockedoutthegene
in X. nematophila by insertional inactivation. Differential
metabolite analysis of organic extracts between the
XNC1_2713 mutant and the wildtype cultures indicated
that xenematide A production (9, 17.3 min) was abolished
in the mutant (Figure 1A). Production of antibiotics
not associated with the NRPS was largely unaffected
(Figure1AB),andtheidentifiedmoleculesincludedxenor-
tide C (1, a new xenortide identified here, C24H34N3O2,
[MþH]
þ at m/z 396.2642, calcd 396.2651, Table S1 and
Figures S1 S5), rhabduscin (2),
2 3,
2 5,
6 10,
2 nematophin
(11),
7 and xenocoumacin (12).
8 Unexpectedly, two peaks
(4, 15.1 min and 6 8, 16.8 min) more polar than xenema-
tide A under reversed phase separation conditions were
also lacking in the mutant. Careful separation of the
peak at 16.8 min revealed three related products (6 8)
produced only in wildtype cultures. High-resolution mass
spectrometry (HR-MS) indicated that 6 8 had molecular
formulas of C33H37N4O6 ([MþH]
þ at m/z 585.2697, calcd
585.2713), C35H38N5O6 ([MþH]
þ at m/z 624.2827, calcd
624.2822), and C35H38N5O6 ([MþH]
þ at m/z 624.2811,
calcd 624.2822), respectively. One-(
1H) and two-(gCOSY,
gHSQC, and gHMBC)-dimensional NMR of the two
compounds with identical masses (7 8) indicated that
both are composed of PAA, Thr, Trp, Phe, and β-Ala
(Figures 2 and S6 S13, Tables S2 S3). The mass data
and long-range HMBC correlations confirmed that the
residues were cyclized, as in xenematide A, and MS/MS
fragmentation analysis confirmed the positioning of the
residues (Figures 2 and S14 S17). These results show that
the two A domains that select Trp in xenematide A bio-
synthesis can accept either Trp or Phe to give a diversified
product scaffold. Notably, this Trp/Phe promiscuity is
accommodated in the downstream domains and results
in a small family of cyclic depsipeptides. Low production
of 6 precluded detailed NMR-based structural character-
ization, but HR-MS and MS/MS fragmentation analysis
combined with the genetic correlation indicates that the
compound contains Phe in both positions 3 and 4. HR-
MS, MS/MS, and NMR analysis of the second peak at
15.1minindicatedthatthemajorxenematideAunderwent
methanolysis during sample processing to the open-chain
form 4 (Table S4 and Figures S18 S23). Under the con-
ditionsoftheexperiment,minorxenematides6 8represent
9% of the total xenematide peak area (4, 6 9; 210 nm),
indicating substantially relaxed substrate selectivity.
XenematideA(9)waspreviouslyshowntocontainboth
an L-a n daD-Trp, but it was unclear which Trp in the
sequence was L or D.
3 The enzyme identified here lacks an
Figure1. (A)Thecyclicpeptides(4,6 9,Figure2)arepresentin
wildtypebutabsentintheNRPSXNC1_2713inactivant.Levels
ofotherorganicextractablemetaboliteswerelargelyunaffected.
(B) L-Proline upregulates production of various metabolites in
the organic extract. Xenocoumacin (12) remains in the aqueous
fraction.
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obvious epimerization (E) domain to flip the stereochem-
istryfrom Lto Dineithermodule.DownstreamCdomains
havesequence-basedstereospecificitysignaturesthatfacil-
itatethepredictionofproductstereochemistry.
9Addition-
ally, specialized C/E domains, particularly in Gram-
negative bacteria, have been shown to both epimerize the
enzyme-boundsubstrateandsubsequentlycondensethe D-
product during chain assembly.
10 Conserved domain da-
tabase analysis of the termination module 4 indicated
tandem C domains (C4a and C4b) with C4b containing
the sequence signature for dual C/E activities (Figures 3
and S24). Recently both possible xenematide diastereo-
mers were synthesized, and spectroscopic comparison
confirmed that D-Trp occupies position 4.
11
WhilethestereochemistryofxenematideAwasresolved
by synthesis, the stereochemistries of the new xenematides
were unknown. Peptides (4, 6 9) were subjected to acid
hydrolysis and advanced Marfey’s analysis.
12 All peptides
werefoundtoincorporate L-Thr.XenematideA(9)andits
methanolysis product 4 contained L-a n dD-Trp as ex-
pected. Xenematide B (6)c o n t a i n e dL-a n dD-Phe, and
based on the positions of D/L-residues in xenematide A (9)
and the bioinformatic analysis, it is likely that D-Phe
occupies position 4. Since xenematides C and D (7 and 8)
consist of a unique selection of amino acids, Marfey’s
analysis alone was sufficient to determine stereochemical
assignments.IrrespectiveofwhetheraTrporPheoccupied
position 4, the amino acid in this position has the D-
configuration.
Thesebioinformatic,genetic,andstructuralresultshigh-
light the unusual aspects of the xenematide biosynthetic
pathway: an absent initiation module, A domain Trp/Phe
promiscuity and its toleration in subsequent steps, and the
role of the tandem C/CE domains in module 4 (Figure 2).
Unlike canonical initiation modules that begin with A-T,
Figure 2. Proposed xenematide biosynthesis. Xenematide A (9) and several new xenematide derivatives B (6), C (7), and D (8) are
shown. Compound 4 is the open chain methanolysis product of xenematide A, which is not shown. Ph, phenyl; Ind, indole.
Figure 3. (A) Key active site residue organization for E, C, and C/E domains. (B) Alignment of active site regions from C and C/E
domains in xenematide and arthrofactin biosynthesis. Active site residues are marked with asterisks.
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NRPS XNC1_2713 begins with a C-A-T module. This
starter module arrangement can be found in NRPS pro-
ducts that are N-acylated, which is consistent with xene-
matide’s 2-phenylacetamide substituent. Free standing A
domains are known to activate aromatic carboxylic acids
and transfer them to aryl-carrier proteins (ArCP), which
are used as starter substrates in, for example, quinoxaline
antibiotics.
13 Since no free-standing A domain and/or an
ArCP are clustered with the XNC1_2713 gene, the poten-
tialstarterproteinsareencodedelsewhereinthegenomeor
phenylacetyl-CoAisusedasastarterunitdirectly.Module
1condensesthePAAstarterunitwithan L-Thr.Modules2
and 3 would variably condense L-Trp and L-Phe with a
preference for L-Trp. Similarly, select modules in the
tyrocidine biosynthetic pathway that activate Phe or Tyr
in tyrocidine A can also activate Trp to produce tyroci-
dines B D, and the relative amount of each tyrocidine is
dependent upon amino acid concentration in the culture
medium.
14 Based on literature precedent, it is not obvious
how the domain arrangement in module 4 could catalyze
condensationofaβ-Alaunit(position5)whileepimerizing
the upstream position 4 (L-Trp or L-Phe). Specialized C/E
domains are capable of upstream epimerization as indi-
cated by the arthrofactin, syringopeptin, and ramoplanin
biosynthetic proteins.
10 The XNC1_2713 C domains were
aligned withthe C domains involvedin the biosynthesis of
the potent cyclic lipopeptide biosurfactant arthrofactin
(Figure 3),
15 and C4a appears to be a typical C domain
whereas C4bhastheC/Esequencesignature.Inone recent
case, multiple adjacent C domains were proposed to con-
dense different lengths of a poly-Lys polymer (variable
substrates) in poly-Lys biosynthesis.
16 However, with the
D-configuration in xenematide position 4 and the C/E
sequence activity only in C4b, it is unlikely that both
domains redundantly catalyze condensation. It is possible
that C4a is nonfunctional, but sequence analysis suggests
an intact domain with active site residues conserved. An
intriguing possibility is that C4a catalyzes condensation
while the apparent C4b domain is a dedicated epimerase,
with both exhibiting relaxed substrate specificity to
accommodate upstream adenylation domain promiscuity.
The last noncanonical residue, β-Ala, serves as a spacer
unit that results in a 14-member rather than a 13-member
macrolactonethatwouldarisefromR-aminoacidssuchas
GlyorAla.Finally,theterminalthioesterase(TE) domain
would catalyze O C macrocyclization and xenematide
product release.
C domains exhibit sequence and structural homology
to E, C/E, and cyclization (Cy) domains.
17 Cy domains
typically catalyze condensation, cyclization, and dehydra-
tion to introduce thiazoline or oxazoline rings into the
peptide product. In vibriobactin biosynthesis, tandem Cy
domains in VibF decouple the condensation and hetero-
cyclization activities of standard Cy domains, and both
domains are required for vibriobactin synthesis.
18 It has
beenproposedthatEdomainsevolvedfromCdomainsby
domainduplicationanddivergentevolution,andthatC/E
domains could have been an E domain precursor.
10 If, as
suggested above, the C and E activities were decoupled in
xenematide biosynthesis, the C C/E pair of XNC1_2713
would provide a functional linksupporting thisevolution-
ary hypothesis.
Thepeculiarfeaturesofxenematidebiosynthesisarenot
limitedtoX.nematophila,ascloseproteinhomologscanbe
identified in the related Xenorhabdus bovienii (id/sim/gap:
65/77/3%) and even in Photorhabdus asymbiotica
(79/87/1%), which forms a mutualistic symbiosis with
Heterorhabditis nematodes that can infect both humans
andinsects.
19TheconservationofthisNRPSpathwayacross
bacterial genera that infect both human and invertebrate
hosts suggests a selective advantage for maintaining its
ability to produce xenematides. Unlike primary metabo-
lism that follows a “one enzyme, one reaction, one pro-
duct” dogma due to large selective pressures for energy
conservation and survival, secondary metabolism fre-
quently features pathways that produce multiple related
products,
20 and this biosynthetic flexibility must represent
some sort of an evolutionary advantage. The variety of
waysinwhichthesenaturallyoccurringpathwaysdiversify
their output also reflects the general importance of the
strategy, and cases from promiscuous processing of the
products of modular pathways are well-known. The xene-
matide diversification strategy;A domain promiscuity
and downstream tolerance;represents another imple-
mentation of the same overall goal.
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